Henry Schein, Inc. · NASDAQ:HSIC
Henry Schein — Henry Schein COVID-19 & Dentistry webinar (November 2020)
40 slides from Henry Schein's conference presentation, Nov 13, 2020
Slide 1: Cases on the Rise, Promising Early Vaccine Results & the Impacts of Persistent Mask-Wearing
Cases on the Rise, Promising Early Vaccine Results & the Impacts of Persistent Mask-Wearing David Reznik, DDS Gary Severance, DDS Director of the Oral Health Center of Executive Leader of Professional Grady Health System’s Infectious Relations, Henry Schein Dental Disease Program
Slide 2: Disclaimer
Disclaimer The webinar and materials that you will view were prepared for general information purposes only by the presenter and are not intended to be a substitute for professional advice, nor purported to be comprehensive. Henry Schein does not guarantee the accuracy or reliability of the informat
Slide 3: Happy Thanksgiving
225355 10/31 ron 23 6/12 te) Cu
Slide 4: U.S. Sets Record for Daily Infections
U.S. Sets Record for Daily Infections Over 10 million; Deaths > 241,182 deaths States with Most Confirmed Cases: • TX: 1,010,364 confirmed cases; 19,337 deaths • CA: 958,878 confirmed cases; 17,864 deaths • FL: 827,380 confirmed cases; 16,964 deaths • NY: 555,710 confirmed cases; 33,770 deaths • IL:
Slide 5: Coronavirus (COVID-19) statistics
Coronavirus (COVID-19) statistics Confirmed cases Atla Sargasso Sea Oce Mexico
Slide 6: Patient Volume Levels – ADA's Health Policy Institute
Patient Volume Levels – ADA’s Health Policy Institute • Patient volume had been holding steady at ~80% of pre-COVID-19 levels but results from the most recent survey showed a drop to 78% • The number of practices reporting "business as usual," has slipped from about 48% in early September to about 3
Slide 7: Location, Location, Location
Location, Location, Location Location Matters! • Dentists practicing in the 20 largest cities reported lower patient volume numbers ❖ On average, patient volume in cities is at 75% of pre-COVID-19 levels • Patient volume is slightly above the national average in rural and smaller urban areas • Nonur
Slide 8: Dental Offices Add 11k Jobs in October
Dental Offices Add 11k Jobs in October But Recovery Remains Sluggish • The report showed dental offices gained 11,000 new jobs last month; it also “found job increases for hospitals of 16,000 new jobs and 14,000 new positions for physician offices.” • The health care industry was hit hard at the ons
Slide 9: COVID-19 2020 Interim Case Definition
COVID-19 2020 Interim Case Definition Clinical Criteria In the absence of a more likely diagnosis at least two of the following symptoms: • fever (measured or subjective) • chills • rigors • myalgia • headache • sore throat • nausea or vomiting • diarrhea • fatigue • congestion or runny nose
Slide 10: COVID-19 2020 Interim Case Definition
COVID-19 2020 Interim Case Definition Clinical Criteria OR, any one of the following symptoms: • cough, • shortness of breath • difficulty breathing • new olfactory disorder • new taste disorder
Slide 11: COVID-19 2020 Interim Case Definition
COVID-19 2020 Interim Case Definition Clinical Criteria OR, severe respiratory illness with at least one of the following: • Clinical or radiographic evidence of pneumonia • Acute respiratory distress syndrome (ARDS) https://wwwn.cdc.gov/nndss/conditions/ coronavirus-disease-2019-covid-19/case-defin
Slide 12: COVID-19 2020 Interim Case Definition
COVID-19 2020 Interim Case Definition Clinical Criteria Laboratory evidence using a method approved or authorized by the FDA or designated authority: • Confirmatory* laboratory evidence: ❖ Detection of severe acute respiratory syndrome coronavirus 2 ribonucleic acid (SARS- CoV-2 RNA) in a clinical o
Slide 13: COVID-19 2020 Interim Case Definition
COVID-19 2020 Interim Case Definition Epidemiological Criteria One or more of the following exposures in the prior 14 days: • Close contact** with a confirmed or probable case of COVID-19 disease • Member of a risk cohort as defined by public health authorities during an outbreak **Close contact is
Slide 14: Criteria to Distinguishing a New Case From an Existing Case
Criteria to Distinguishing a New Case From an Existing Case • A repeat positive test for SARS-CoV-2 RNA using a molecular amplification detection test within 3 months of the initial report should not be enumerated as a new case for surveillance purposes • To date, there has been minimal evidence of
Slide 15: Case Classification
Case Classification • Suspect • Meets supportive laboratory evidence*** with no prior history of being a confirmed or probable case ❖ *** For suspect cases (positive serology only), jurisdictions may opt to place them in a registry for other epidemiological analyses or investigate to determine proba
Slide 16: References for CDC Case Definitions
References for CDC Case Definitions 1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151. DOI:10.3760/cma.j.issn.0254-6
Slide 17: Interview with Dr. Fauci and the AMA
Interview with Dr. Fauci and the AMA Chronic COVID? “We do know for absolutely certain that there is a post COVID-19 syndrome—referred to sometimes as 'long COVID,' 'chronic COVID,' 'long haulers.' It's got different names,” per Dr. Fauci. There is a program in Bethesda, where the National Institute
Slide 18: Interview with Dr. Fauci and the AMA - MedicalXpress
Interview with Dr. Fauci and the AMA - MedicalXpress Chronic COVID? “One study of 143 people with COVID-19 discharged from a hospital in Rome found that 53% had reported fatigue and 43% had shortness of breath an average of 2 months after their symptoms started,” reports Nature. “A study of patients
Slide 19: COVID-19 is a complex illness that might require ongoing clinical care
COVID-19 is a complex illness that might require ongoing clinical care even after being discharged from the hospital patients hospitalized for COVID-19 were readmitted to the same hospita within 2 months ae tf ae : ma nee, JM ag. UW) Have been hospitalized withir Have been discharged toa aithcare Da
Slide 20: Navigating "the COVID Literature Tsunami"
Navigating “the COVID Literature Tsunami” • We have now learned enough about COVID-19 to provide effective supportive care for most patients with severe illness, provided that health care systems are not overwhelmed • In the sickest patients, we have learned that it is an overly exuberant inflammato
Slide 21: What Areas of COVID-19 Research Have Evolved The Most Rapidly?
What Areas of COVID-19 Research Have Evolved The Most Rapidly? During the Pandemic • COVID-19 diagnostics have evolved rapidly, although there continues to be issues with supply chains that are preventing more widespread implementation of testing at some locations • Regarding therapeutics, we have l
Slide 22: What Areas of COVID-19 Research Have Evolved The Most Rapidly?
What Areas of COVID-19 Research Have Evolved The Most Rapidly? During the Pandemic • Novel adaptive trial designs can quickly evaluate multiple agents and combinations of agents, as has been demonstrated in the NIH- sponsored ACTIV studies • Vaccine development has progressed remarkably quickly!
Slide 23: Areas in Need of More Research
Areas in Need of More Research • What is the influence of prior exposure to endemic seasonal coronaviruses? ❖ There is evidence that prior exposure may be associated with milder illness, but other observations suggest the potential for detrimental cross-reactive immune responses • Another important
Slide 24: Transmission of SARS-CoV-2 Infections in Households
Transmission of SARS-CoV-2 Infections in Households Tennessee and Wisconsin, April – September 2020 Weekly / November 6, 2020 / 69(44);1631-1634 • What is already known about this topic? ❖ Transmission of SARS-CoV-2 occurs within households; however, transmission estimates vary widely and the data o
Slide 25: Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy
Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy • What is already known about this topic? ❖ Pregnant women with SARS-CoV-2 infection are at increased risk for severe illness compared with nonpregnant women ❖ Adverse pregnancy outcomes such as preterm birth
Slide 26: CDC MMWR – References
CDC MMWR – References Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020 Weekly / November 6, 2020 / 69(44);1631– 1634 ❖ https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e1.htm?s_cid=mm6944e1_e&ACSTrackingID=US CDC_921-DM41992&ACSTrackingLabel=This%20Week
Slide 27: Exploring Lessons Learned on Applying Safety & Quality Skills
Exploring Lessons Learned on Applying Safety & Quality Skills 4 Lessons to Help Clinicians Lead Their Organizations to Success • Lesson 1 — Establish a formal, continuous improvement process to drive change • Lesson 2 — Concentrate on the immediate and highest priority concerns and use data and info
Slide 28: Exploring Lessons Learned on Applying Safety & Quality Skills
Exploring Lessons Learned on Applying Safety & Quality Skills 4 Lessons to Help Clinicians Lead Their Organizations to Success • Lesson 3 — Translate the research into meaningful action and disseminate findings rapidly across organizations—and across countries ❖ To illustrate this concept in action,
Slide 29: Exploring Lessons Learned on Applying Safety & Quality Skills
Exploring Lessons Learned on Applying Safety & Quality Skills 4 Lessons to Help Clinicians Lead Their Organizations to Success • Lesson 4 — Remember to always keep the patient and family at the center of your efforts (involving them in the improvement process) ❖ “Regardless of the conditions and cha
Slide 30: Daily Mask Wearing is Hard on Skin
Daily Mask Wearing is Hard on Skin What To Do for “Maskne” and Facial Bruises “Maskne” is the new term that was coined during the pandemic to describe acne under facial masks. It is at an all-time high with the general public and healthcare providers. • This type of acne is called acne mechanica • “
Slide 31: Daily Mask Wearing is Hard on Skin
Daily Mask Wearing is Hard on Skin What To Do for “Maskne” and Facial Bruises • Dr. Khetarpal recommends these simple steps to improve skin health under your mask: 1) Wash your face with a gentle, mild soap-free cleanser; this will remove excess dirt and oil that clogs the pores and causes breakouts
Slide 32: Daily Mask Wearing is Hard on Skin
Daily Mask Wearing is Hard on Skin What To Do for “Maskne” and Facial Bruises Dr. Khetarpal says contact dermatitis is another mask issue. This is an allergic reaction to any of the components of a mask, such as dyes, rubber, and fabrics. This presents as a rash and can be very itchy. If this occurs
Slide 33: Pfizer + BioNTech Report Very Promising Results
Pfizer + BioNTech Report Very Promising Results COVID-19 Vaccine • The drug maker Pfizer announced on Monday that an early analysis of its coronavirus vaccine trial suggested the vaccine was robustly effective in preventing COVID-19 • Pfizer, which developed the vaccine with the German drug maker Bi
Slide 34: Efficacy Comparisons Per CDC.gov
Efficacy Comparisons Per CDC.gov Putting in context with Pfizer & BioNTech’s 90% efficacy: Measles 2 doses 97% efficacy Smallpox 95% efficacy Chickenpox 92% efficacy Seasonal flu 40 – 60% efficacy
Slide 35: Pfizer + BioNTech Report Very Promising Results
Pfizer + BioNTech Report Very Promising Results COVID-19 Vaccine • Pfizer plans to ask the Food and Drug Administration (FDA) for emergency authorization of the two-dose vaccine later this month, after it has collected the recommended two months of safety data • By the end of the year, it will have
Slide 36: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19
FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy Bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is
Slide 37: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19
FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. Bamlanivimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-
Slide 38: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19
FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 While the safety and effectiveness of this investigational therapy continues to be evaluated, Bamlanivimab was shown in clinical trials to reduce COVID-19- related hospitalization or emergency room visits in patients at high risk for disea
Slide 39: Happy Thanksgiving
Slide 40: Thank You!
Thank You! Have topics you’d like us to cover in the next webinar on COVID-19 & Dentistry? • Email: webinars@henryschein.com • Subscribe on YouTube! • Complete post-webinar survey Next Session: Friday, December 11, 2 PM ET
Henry Schein — Henry Schein COVID-19 & Dentistry webinar (November 2020) on 6ix